Please take a moment to review the latest ASCO News
- FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
- COVID-19 Public Health Emergency Extended Through Late April
- Medicare Physician Fee Schedule Conversion Factor Updated to Reflect 2021 Federal Funding Package
- Extend Key Regulatory Flexibilities and Leverage New Technologies During Pandemic and Beyond
- Second Court Blocks Most Favored Nation Model Implementation
- Standardized, Streamlined Processes Key to Implementing Electronic Prior Authorization
- New Research Statement Recommends Streamlining and Standardizing Clinical Trial Site Feasibility Assessments
- Court Ruling: Delaying Most Favored Nation Rule Important First Step Toward Ending Flawed Model
- ASCO Advocates for Priority Status for Cancer Patients in COVID-19 Vaccine Distribution Plans; Provides Information on Safety and Efficacy of Vaccinations
- Congress Passes Sprawling Year-End Legislative Package that Impacts Cancer Research and Delivery
- ASCO Applauds Congress for Expanding Clinical Trial Access for Medicaid Beneficiaries
- FDA Approves Osimertinib as Adjuvant Therapy for Non-small Cell Lung Cancer with EGFR Mutations
- CMS Releases Most Favored Nation Drug HCPCS Codes List and Drug Pricing File for January 1 Implementation
- FDA Approves Selinexor for Refractory or Relapsed Multiple Myeloma
- FDA Approves Relugolix for Advanced Prostate Cancer